Clinical Trials Directory

Trials / Conditions / Metastatic Castrate Resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer

16 registered clinical trials studyying Metastatic Castrate Resistant Prostate Cancer — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingStudy of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Pros
NCT06702995
Evopoint Biosciences Inc.Phase 1 / Phase 2
RecruitingCarboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
VA Office of Research and DevelopmentPhase 2
TerminatedMGC018 With or Without MGA012 in Advanced Solid Tumors
NCT03729596
MacroGenicsPhase 1 / Phase 2
CompletedFractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
NCT03737370
Tufts Medical CenterPhase 1
TerminatedIdronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer
NCT03041285
Royal North Shore HospitalPhase 1
CompletedPhase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cance
NCT02987829
Tracon Pharmaceuticals Inc.Phase 1 / Phase 2
SuspendedDetection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
NCT03236688
Exosome Diagnostics, Inc.—
TerminatedSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In C
NCT02607228
Gilead SciencesPhase 1 / Phase 2
CompletedMasitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT03761225
AB SciencePhase 3
Active Not RecruitingA Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Inj
NCT02266745
Promontory Therapeutics Inc.Phase 2
CompletedObservational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT02008058
UNC Lineberger Comprehensive Cancer Center—
CompletedSipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer
NCT01818986
University of Texas Southwestern Medical CenterPhase 2
TerminatedA Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistan
NCT01732549
IpsenPhase 2
TerminatedOGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Rece
NCT01681433
Costantine AlbanyPhase 2
CompletedPharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dos
NCT01540526
University of Wisconsin, MadisonPhase 1
CompletedA Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
NCT01090765
National Cancer Institute (NCI)Phase 1 / Phase 2